Cite
Bristol-Myers Squibb and Pfizer reported negative preliminary results from a phase III trial of apixaban for the prevention of venous thromboembolism (VTE)
MLA
“Bristol-Myers Squibb and Pfizer Reported Negative Preliminary Results from a Phase III Trial of Apixaban for the Prevention of Venous Thromboembolism (VTE).” CenterWatch Weekly, vol. 12, no. 35, 2 Sept. 2008, p. 7. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.188643754&authtype=sso&custid=ns315887.
APA
Bristol-Myers Squibb and Pfizer reported negative preliminary results from a phase III trial of apixaban for the prevention of venous thromboembolism (VTE). (2008, September 2). CenterWatch Weekly, 12(35), 7.
Chicago
CenterWatch Weekly. 2008. “Bristol-Myers Squibb and Pfizer Reported Negative Preliminary Results from a Phase III Trial of Apixaban for the Prevention of Venous Thromboembolism (VTE),” September 2. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.188643754&authtype=sso&custid=ns315887.